Those who had 2 COVID infections were 2.14 times more likely, and those who had 3 or more COVID infections were 3.75 times more likely, to report #LongCOVID than those with one infection.
2/
The odds of both severe fatigue and post-exertional malaise, two debilitating symptoms, increased with reinfections. 3/ #LongCovid
The frequency and severity of post-exertional malaise (PEM) increased with reinfections. 4/ #LongCovid
The severity of fatigue, as measured by the Fatigue Severity Scale, also increased with reinfections. 5/ #LongCovid
The odds of having limitations to physical functioning increased with COVID reinfections, including bathing and dressing limitations, limitations to moderate activity such as pushing a vacuum cleaner, and social limitations. 6/ #LongCovid
Reinfections increased the odds of reporting poor immune health, including having had many other infections and taking longer to recover from common infections. 7/ #LongCovid
The number of vaccines and boosters prior to an infection reduced the odds of Long COVID, but their protective effect was diminished by reinfections. 8/
For those who menstruated, reinfections were associated with worsening of ongoing or chronic health issues related to the menstrual cycle. 9/ #LongCovid
The paper is full of interesting findings, but a few others that stand out:
Only a small percentage reported being prescribed antivirals for acute COVID. 10/
Participants were less likely to report getting a COVID test the more reinfections they experienced, likely due to decreased societal testing over time.
However: they were more likely to test if someone around them tested positive. 11/
Trans, nonbinary, agender, and other gender nonconforming people were less likely to report being prescribed medication for acute COVID. 12/ #LongCovid
The co-authors are all PLRC (@patientled) members who are researchers & have #LongCovid, with affiliations at UCSF, Yale, Howard Hughes Medical Institute, U of Wyoming, U of Bern, U of Bristol, @LongCovidChile & Black COVID-19 Survivors Alliance (@BCSAlliance).
13/
@LongCovidChile @BCSAlliance This was a huge effort over years - thank you @leticiasaurus @TheMegascope & @GinaAssaf for leading & @LisaAMcCorkell @ahandvanish Alison Cohen @jannamoen @LG_Shoemaker Leo Liu @dsethlewis @rach_r0bles @rusty_cjm Jerry Lin, Teri Akintonwa, @ssaraviaandre & @herlifeinpixels! 14/
• • •
Missing some Tweet in this thread? You can try to
force a refresh
Population-wide, 10.4% of people with pre-existing disabilities had #LongCovid as of summer 2022, vs 7.5% without. 2/
The prevalence of #LongCovid was highest in those with chronic illness (diabetes, asthma) & lowest in those with sensory disabilities (deafness, blindness).
With the exception of sensory disabilities, all disability categories had higher LC rates than the general population. 3/
We’ve released a new paper on designing & optimizing clinical trials for #LongCOVID!
Strong, high-impact trials are critical & most current ones are insufficient. The paper gives guidance on treatments, outcomes, design, participant inclusion, & more.
It also gives an overview of the promising interventions being trialed (as of May 2024) for #LongCovid and their targets, including viral persistence, immune dysfunction, endothelial dysfunction, and symptom management. 2/
Some other key points:
-Trials should prioritize potentially curative interventions, including repurposed drugs and the development of new drugs.
-Combinations of therapies may be beneficial or necessary, which should be considered in clinical trial design. 3/
We are happy to announce a new #LongCovid review out in Nature!
This was led by @zalaly, with co-authors @leticiasaurus @LisaAMcCorkell and @ahandvanish from PLRC, alongside @VirusesImmunity, @EricTopol, and @swulfie.
Today, we are thrilled to see the introduction of The Long COVID Research Moonshot Act by Senator Bernie Sanders (@SenSanders), co-sponsored by Senators @SenTimKaine, @SenDuckworth, @SenMarkey, @SenPeterWelch, and @SenTinaSmith!
9 months ago, our co-founder Lisa McCorkell (@LisaAMcCorkell) & Long COVID researcher Michael Peluso (@MichaelPelusoMD) called for a Moonshot for Long Covid - an investment of at least $1 billion yearly for 10 years into Long Covid research. 2/
The Act is a historic piece of legislation. It includes $1 billion/yr for 10 years to NIH to establish & run a #LongCovid Research Program, led by a Director with expertise in Long COVID. Clinical trials & the development of new interventions would be prioritized & expedited. 3/
"Long COVID is an IACC that occurs after SARS-CoV-2 infection & is present for at least 3 months as a continuous, relapsing and remitting, or progressive disease state that affects one or more organ systems"
Full report & thoughts👇🧵/1
This #LongCovid definition was developed by @theNASEM — commissioned by @HHSGov through @ASPRgov & OASH — to promote consistency in diagnoses, aid awareness efforts, help patients access care & benefits, harmonize LC research, & public health monitoring/regulations /2
1 pager👇
The definition can be used in clinical care, public health policy, & gives researchers/healthcare workers both consistency & flexibility in studying #LongCovid. Importantly, it also emphasizes how health equity is impacted by & impacts LC. /3
@polybioRF Dr. Amy Proal @polybioRF kicking things off with the history of the foundation, its Long Covid Research Consortium, and its focus on the viral persistence hypothesis. This culminated in this position paper published last year. 1/nature.com/articles/s4159…
@polybioRF Now, the focus is on Phase 2, exploring mechanisms/locations of persistence, connections to other conditions, and clinical trials. 2/